Literature DB >> 31330166

Burden of surgical site infections in the Netherlands: cost analyses and disability-adjusted life years.

M B G Koek1, T I I van der Kooi2, F C A Stigter3, P T de Boer2, B de Gier2, T E M Hopmans2, S C de Greeff2.   

Abstract

BACKGROUND: Surgical site infections (SSIs) are associated with morbidity, mortality and costs. AIM: To identify the burden of (deep) SSIs in costs and disability-adjusted life years (DALYs) following colectomy, mastectomy and total hip arthroplasty (THA) in the Netherlands.
METHODS: A retrospective cost-analysis was performed using 2011 data from the national SSI surveillance network PREZIES. Sixty-two patients with an SSI (exposed) were matched to 122 patients without an SSI (unexposed, same type of surgery). Patient records were studied until 1 year after SSI diagnosis. Unexposed patients were followed for the same duration. Costs were calculated from the hospital perspective (2016 price level), and cost differences were tested using linear regression analyses. Disease burden was estimated using the Burden of Communicable Disease in Europe Toolkit of the European Centre for Disease Prevention and Control. The SSI model was specified by type of surgery, with country- and surgery-specific parameters where possible.
FINDINGS: Attributable costs per SSI were €21,569 (THA), €14,084 (colectomy) and €1881 (mastectomy), mainly caused by prolonged length of hospital stay. National hospital costs were estimated at €10 million, €29 million and €0.6 million, respectively. National disease burden was greatest for SSIs following colectomy (3200 DALYs/year, 150 DALYs/100 SSIs), while individual disease burden was highest following THA (1200 DALYs/year, 250 DALYs/100 SSIs). For mastectomy, these DALYs were <1. The total cost of DALYs for the three types of surgery exceeded €88 million.
CONCLUSION: Depending on the type of surgery, SSIs cause a significant burden, both economically and in loss of years in full health. This underlines the importance of appropriate infection prevention and control measures.
Copyright © 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Burden; Costs; Disability-adjusted life years; Disease burden; Economic burden; Infection prevention; Prevention; Surgical site infection; Surveillance

Mesh:

Year:  2019        PMID: 31330166     DOI: 10.1016/j.jhin.2019.07.010

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

1.  The Impacts of Deep Surgical Site Infections on Readmissions, Length of Stay, and Costs: A Matched Case-Control Study Conducted in an Academic Hospital in the Netherlands.

Authors:  Abdul Khairul Rizki Purba; Christian F Luz; Riyanti R Wulandari; Ieneke van der Gun; Jan-Willem Dik; Alex W Friedrich; Maarten J Postma
Journal:  Infect Drug Resist       Date:  2020-09-30       Impact factor: 4.003

2.  Economic impact of a care bundle to prevent surgical site infection after craniotomy: a cost-analysis study.

Authors:  Emilio Jiménez-Martínez; Guillermo Cuervo; Jordi Carratalà; Ana Hornero; Pilar Ciercoles; Andreu Gabarrós; Carmen Cabellos; Ivan Pelegrin; Maria Angeles Domínguez-Luzón; Jordi Càmara; Ramon Moreno-Fuentes; Jordi Adamuz; Miquel Pujol
Journal:  Antimicrob Resist Infect Control       Date:  2021-10-13       Impact factor: 4.887

3.  Ceramic-on-Ceramic Bearing in Total Hip Arthroplasty Reduces the Risk for Revision for Periprosthetic Joint Infection Compared to Ceramic-on-Polyethylene: A Matched Analysis of 118,753 Cementless THA Based on the German Arthroplasty Registry.

Authors:  Lisa Renner; Carsten Perka; Oliver Melsheimer; Alexander Grimberg; Volkmar Jansson; Arnd Steinbrück
Journal:  J Clin Med       Date:  2021-03-12       Impact factor: 4.241

4.  Reliability and validity of multicentre surveillance of surgical site infections after colorectal surgery.

Authors:  Janneke D M Verberk; Stephanie M van Rooden; David J Hetem; Herman F Wunderink; Anne L M Vlek; Corianne Meijer; Eva A H van Ravensbergen; Elisabeth G W Huijskens; Saara J Vainio; Marc J M Bonten; Maaike S M van Mourik
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-21       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.